Amdipharm and Mercury Pharma merge
As has been expected, Amdipharm and Mercury Pharma - both subsidiaries of Channel Islands-based private equity firm Cinven - have merged to create a single, consolidated, international speciality pharmaceuticals company, to be called Amdipharm Mercury Company Limited, abbreviated to AMCo.
John Beighton has been appointed chief executive of AMCo, which will have pro forma revenues of £250 million ($373 million) a year and operations in 112 territories. An important part of AMCo’s strategy will be further product and company acquisitions, which are expected to be announced in the coming days.
“We believe that the merger will allow us to provide an even better service to our partners and to patients, strengthening the close relationships we have forged over the past 25 years,” said Mr Beighton.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze